New models support comparative research, more nonprescription drugs Full Text
Formulary , 07/05/2012
The drive for personalized medicine and greater patient involvement in treatment decisions demands more informative data on the effects and risks associated with drugs and medical products. FDA seeks to facilitate informed self–treatment with a proposal for expanding access to more over–the–counter (OTC) drugs with additional "conditions for safe use." Government support for comparative effectiveness research (CER) is attracting great interest from researchers, payers, and pharmaceutical companies looking to identify optimal treatment for a broad range of medical conditions.